

AN 1998:293388 CAPLUS  
 DN 129:599  
 TI Combination therapy for the treatment of diabetes and obesity  
 IN Smith, Roy G.; Cascieri, Margaret A.; MacIntyre, Euan; MacNeil, Douglas J.; Menke, John G.  
 PA Merck & Co., Inc., USA; Smith, Roy G.; Cascieri, Margaret A.; Macintyre, Euan; Macneil, Douglas J.; Menke, John G.  
 SO PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818481	A1	19980507	WO 1997-US19880	19971030
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9851606	A1	19980522	AU 1998-51606	19971030
	AU 723879	B2	20000907		
	US 5908830	A	19990601	US 1997-961749	19971030 <--
	EP 969852	A1	20000112	EP 1997-946442	19971030
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	JP 2002516605	T2	20020604	JP 1998-520803	19971030
PRAI	US 1996-29233P	P	19961031		
	GB 1997-11042	A	19970530		
	WO 1997-US19880	W	19971030		

AB The combination of a metabolic rate-modifying agent (e.g., a .beta.3 adrenergic receptor agonist) and a feeding behavior modifying agent (e.g., a NPY5 antagonist) is useful in the treatment of obesity and diabetes, either as compds., pharmaceutically acceptable salts, or pharmaceutical compn. ingredients. Methods of treating obesity and diabetes are also described.

IT 128908-32-7, Melanocortin  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (agonists; combination therapy for the treatment of diabetes and obesity)

RN 128908-32-7 CAPLUS  
 CN Melanocortin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs 1-11

L12 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:217986 CAPLUS  
 DN 138:238445  
 TI Melanocortin receptor-3 ligands for treating sexual dysfunction  
 IN Dines, Kevin C.; Gahman, Timothy C.; Girtten, Beverly E.; Hitchin, Douglas L.; Holme, Kevin R.; Lang, Hengyuan; Slivka, Sandra R.; Watson-Straughan, Karen J.; Tuttle, Ronald R.; Pei, Yazhong  
 PA Lion Bioscience AG, Germany  
 SO U.S., 25 pp., Cont.-in-part of U.S. Ser. No. 364,825, abandoned.  
 CODEN: USXXAM  
 DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6534503	B1	20030318	US 2000-615479	20000713 <--
	US 6127381	A	20001003	US 1999-301391	19990428 <--
	US 6284735	B1	20010904	US 1999-356386	19990716 <--
PRAI	US 1998-83368P	P	19980428		
	US 1999-301391	A1	19990428		
	US 1999-306686	A2	19990506		
	US 1999-356386	A2	19990716		
	US 1999-364825	B2	19990730		
	US 1999-401004	A2	19990921		

OS MARPAT 138:238445

AB Methods are described for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with peptides having the sequence -D-Phe-Arg-D-Trp-. A particularly useful compd. is HP-228 (Ac-Nle-Gln-His-D-Phe-Arg-D-Trp-Gly-NH<sub>2</sub>), which was prepd. by the solid-phase method and assayed for biol. activity. The invention also provides methods for selecting melanocortin receptor-3 ligands by detg. whether a compd. modulates the activity of MC-3 as an agonist or antagonist. These methods can be used to screen compd. libraries (e.g., benzimidazole derivs., which are claimed) for ligands to treat MC-3-assocd. conditions.

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 16

L7 3 L6

=> d bib abs hitstr 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2002:777885 CAPLUS

DN 137:295252

TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors

IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 116 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079146	A2	20021010	WO 2002-US6581	20020302
	WO 2002079146	A3	20030206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
OS	MARPAT 137:295252				
GI					



I

AB Compds. W-(CH<sub>2</sub>)<sub>y</sub>(CR<sub>4</sub>R<sub>5</sub>)<sub>x</sub>CO-X(R<sub>1</sub>)CHR<sub>2</sub>(CHR<sub>3</sub>)<sub>r</sub>(CH<sub>2</sub>)<sub>s</sub>CO-E [X = N or CH; R<sub>1</sub>, R<sub>3</sub> = H or alkyl; R<sub>2</sub> = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R<sub>1</sub> together with R<sub>2</sub> or R<sub>3</sub> or R<sub>2</sub> together with R<sub>3</sub> form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or

heterocyclyl; E = (un)substituted pyrrolidino, piperidino, or hexahydro-1-azepinyl; R4, R5 = H, (un)substituted alkyl, halo, hydroxy, amino, aryl, cycloalkyl, heterocyclyl, spirocycloalkyl ring; r, s = 0 or 1; x, y = 0-4; W = amino, carbamoyl, amidino, guanidino, heteroaryl, heterocyclyl, etc.] or their pharmaceutically-acceptable salts or prodrugs were prepd. as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepd. by a soln.-phase peptide coupling/deprotection scheme.

IT 457895-17-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457895-17-9 CAPLUS

CN Carbamic acid, [(1S)-1-(1H-imidazol-4-ylmethyl)-2-[[[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2002:695975 CAPLUS

DN 137:232913

TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors

IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070511	A1	20020912	WO 2002-US6479	20020302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 PRAI US 2001-273206P P 20010302  
 US 2001-273291P P 20010302  
 OS MARPAT 137:232913  
 GI



AB Compds. W-(CR6R7)yCH(G)(CR4R5)xCO-X(R1)CHR2(CHR3)r(CH2)sCO-E [X = N or CH; R1, R3 = H or alkyl; R2 = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R1 together with R2 or R3 or R2 together with R3 form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, hexahydro-1-azepinyl, 1-piperazinyl, cyclopentyl, cyclohexyl, cycloheptyl, amino, (cyclo)alkylamino; R4-R6 = H, (un)substituted alkyl, amino, alkylamino, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, or heterocyclyl; or CR4R5 or CR6R7 is a spirocycloalkyl ring; r, s = 0 or 1; x = 0-4; y = 0-2; G = alkenyl, arylalkenyl, hydroxy, heteroaryl, cyano, functionalized alkyl or alkenyl, etc.; W = amino, alkylamino, hydroxy, alkoxy, carbamoyl, amidino, cycloalkyl, heteroaryl, heterocyclyl, etc.] were prepd. as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepd. by a soln.-phase peptide coupling/deprotection scheme.


IT 457895-17-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457895-17-9 CAPLUS

CN Carbamic acid, [(1S)-1-(1H-imidazol-4-ylmethyl)-2-[[[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2002:695727 CAPLUS

DN 137:226646

TI Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

IN Macor, John E.; Carlson, Kenneth E.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069905	A2	20020912	WO 2002-US6805	20020304
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003069169	A1	20030410	US 2002-90258	20020304
PRAI	US 2001-273206P	P	20010302		
	US 2001-273291P	P	20010302		
	US 2001-289719P	P	20010509		
OS	MARPAT 137:226646				
AB	Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenosine 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatitis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.				
IT	457895-17-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-assocd. disorders)				
RN	457895-17-9	CAPLUS			
CN	Carbamic acid, [(1S)-1-(1H-imidazol-4-ylmethyl)-2-[[[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

